Olpha

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages) This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Olpha" – news · newspapers · books · scholar · JSTOR (March 2015) (Learn how and when to remove this message) This article contains promotional content. Please help improve it by removing promotional language and inappropriate external links, and by adding encyclopedic text written from a neutral point of view. (December 2017) (Learn how and when to remove this message) (Learn how and when to remove this message)

Olpha JSC

Company type	Public
Traded as	Nasdaq Baltic: OLF1R
Industry	Pharmaceuticals
Predecessor	Olaine Chemical-Pharmaceutical Plant
Founded	10 October 1972
Headquarters	Rūpnīcu 5, Olaine , Latvia
Area served	Worldwide
Revenue	113,537,000 Euro (2022)
Net income	18,143,000 Euro (2022)
Total assets	196,314,000 Euro (2022)
Owner	JSC AB City
Number of employees	1,054 (2022)
Website	http://www.olpha.eu

JSC Olpha (till 19.06.2024 the company' name was JSC Olainfarm) is a Latvian leading manufacturer in the chemical and pharmaceutical sector of the Baltic States.^[1]

The company was founded in 1972 as state enterprise "Olaines ķīmiski – farmaceitiskā rūpnīca" (Olaine Chemical-Pharmaceutical Plant). The main goal of founding the company was to supply pharmaceutical substances and intermediates to several finished drug form manufacturing plants in the Soviet Union. As a result of privatization in 1997, the company was reorganized into a joint stock company, and its shares were listed on the stock exchange.

Olainfarm produces over 60 final dosage forms,^[2] 25 active pharmaceutical ingredients^[3] and 20 intermediates.^[4] The product portfolio is well diversified with the main emphasis on branded products, historically unique to Olainfarm. The key areas of specialization in final dosage forms include neurology (cholinesterase inhibitors, anxiolytics, psychostimulants, nootropics), cardiology (antiarrhythmics, energy metabolism enhancers), infectology (original nitrofurantoine derivatives and antivirals) and allergology (fast acting antihistamines).

Olainfarm is certified in accordance with the requirements of the EU GMP for APIs and FDFs, the U.S. cGMP for certain APIs (FDA), TGA for FDFs (Australia), CEP for certain APIs, ISO 14001 Environmental Management System and ISO 17025 Laboratory Management System.^[5]

Proof of the high quality of the Olainfarm products is cooperation with such global and regionally acknowledged companies as Novartis, Dr. Reddy's, Glenmark Generics, Sigma AU, Almirall Ranke, UQUIFA, MIAT, Actavis, Teva, Egis, PHF and many others. Since 2011 Olainfarm supplies anti-tuberculosis medication to the World Health Organization.^[6]